Developing Better Methods of Cross-Reactive Influenza Vaccine Production
•Download as PPTX, PDF•
0 likes•46 views
This poster presents a potential approach to developing a influenza vaccine that combats common problems encountered in contemporary vaccination methods. By utilizing Virus Like Particles as well as Tandem Core LAH technology, the influenza vaccine could be widely effective, effective across multiple strains of influenza, and could be produced in a small time frame. This project was created as part of a course designed to provide applications of Biological Engineering at Worcester Polytechnic Institute.
Report
Share
Report
Share
Recommended
VACCINES AND ITS PRODUCTION
This document discusses the production and manufacturing of vaccines. It describes two main types of vaccine production: traditional egg-based methods and newer cell-based methods using mammalian cells. The egg-based methods have been used for 60 years to produce seasonal flu vaccines but they have disadvantages like mutations during adaptation and long production times. Cell-based methods using dog kidney cells or other mammalian cells have advantages like faster production and reduced mutations but they have higher costs. The document also mentions clinical development of vaccines during a pandemic is urgent to protect the public with limited time constraints.
Ai tool can predict covid19 mutation and vaccine efficacy
A new machine learning model developed by researchers at the University of Southern California can design vaccines much faster than traditional methods, potentially in minutes rather than months or years. The model evaluated potential Covid-19 treatments and identified the best options, eliminating 95% of compounds. It could also quickly design new preventative measures if current vaccines become ineffective against mutations. Engineers believe the tool may one day be able to design new vaccines for novel viruses in under a minute.
09 CeoMeeting- Session 4- Sentinext
Session 4: Health & Wellness
Title: The Changing Face Of Healthcare:
Where Are The Opportunities?
Mr Peter Wulff, Sentinext Therapeutics
Diagnostics to reduce antimicrobial (mis)use
Poster prepared by Elise Schieck, Caroline Fossum, Bernt Hjertner and Claudia Lutzelschwab for the Virtual Livestock CRP Planning Meeting, 8-17 June 2020
Medical eggs
The document discusses the use of chicken eggs in producing flu vaccines. It notes that most flu vaccines are currently produced using chicken eggs, though this process has limitations like being time-consuming and requiring a reliable egg supply far in advance. Researchers are working on alternative production methods like using chicken eggs to produce antigens or developing a universal flu vaccine. The document provides various links to databases and information on using eggs in medical and pharmaceutical applications.
Hawaii - Vaccine Research - Advancing Humanity - Invest in Our Future
Hawaii - Vaccine Research - Advancing Humanity - Invest in Our FutureClifton M. Hasegawa & Associates, LLC
The document discusses the need for vaccines and exit strategies to end the COVID-19 crisis. It highlights research at the University of Hawaii that shows promise for a COVID-19 vaccine. The vaccine candidate developed by Dr. Axel Lehrer and his team successfully stimulated antibody and immune responses in mice, demonstrating potential to provide protection against SARS-CoV-2. If further research is successful, this could provide a path towards resolving the global pandemic.Mark Lipsitch: "Simulation and Deliberation to Prepare for Clinical Trials in...
Mark Lipsitch: "Simulation and Deliberation to Prepare for Clinical Trials in...The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics
Infectious disease emergencies are opportunities to test the efficacy of newly developed interventions (e.g. drugs, vaccines and treatment regimens), yet they raise many intertwined challenges of politics, logistics, ethics, and study design. Consistent with the efforts of CEPI, WHO, and others to encourage development and Phase I/II testing of candidate vaccines (the focus of this talk) in advance of emergencies, it is essential before the emergency strikes to advance the discussion of how such products can and should be tested. This can help to disentangle ethical from political and logistical concerns, reduce the time pressure to make a decision, and encourage rational deliberation by future stakeholders who at the time of deliberation do not know what role (which product, which field site) they may be supporting in an actual emergency.
At this luncheon, Professor Marc Lipsitch described his work on computer simulation of vaccine trials during epidemics to assess options for trial design, as well as some of his recent work on the ethics of trials in emergencies, with the aim to stimulate discussion on the intersection of these two topics.
For more, please see our website: http://petrieflom.law.harvard.edu/events/details/digital-health-harvard-series-november-2018Aaron Gilbertie and Dr. Jessica Seate - Welcome To The Aptimmune Symposium
Welcome To The Aptimmune Symposium - Aaron Gilbertie, CEO, Aptimmune; Dr. Jessica Seate, Professional Services Veterinarian, Aptimmune, from the 2018 Aptimmune Pre-AASV Symposium, March 2, 2018, San Diego, CA, USA.
More presentations at http://www.swinecast.com/2018-aptimmune-symposium-aasv
Recommended
VACCINES AND ITS PRODUCTION
This document discusses the production and manufacturing of vaccines. It describes two main types of vaccine production: traditional egg-based methods and newer cell-based methods using mammalian cells. The egg-based methods have been used for 60 years to produce seasonal flu vaccines but they have disadvantages like mutations during adaptation and long production times. Cell-based methods using dog kidney cells or other mammalian cells have advantages like faster production and reduced mutations but they have higher costs. The document also mentions clinical development of vaccines during a pandemic is urgent to protect the public with limited time constraints.
Ai tool can predict covid19 mutation and vaccine efficacy
A new machine learning model developed by researchers at the University of Southern California can design vaccines much faster than traditional methods, potentially in minutes rather than months or years. The model evaluated potential Covid-19 treatments and identified the best options, eliminating 95% of compounds. It could also quickly design new preventative measures if current vaccines become ineffective against mutations. Engineers believe the tool may one day be able to design new vaccines for novel viruses in under a minute.
09 CeoMeeting- Session 4- Sentinext
Session 4: Health & Wellness
Title: The Changing Face Of Healthcare:
Where Are The Opportunities?
Mr Peter Wulff, Sentinext Therapeutics
Diagnostics to reduce antimicrobial (mis)use
Poster prepared by Elise Schieck, Caroline Fossum, Bernt Hjertner and Claudia Lutzelschwab for the Virtual Livestock CRP Planning Meeting, 8-17 June 2020
Medical eggs
The document discusses the use of chicken eggs in producing flu vaccines. It notes that most flu vaccines are currently produced using chicken eggs, though this process has limitations like being time-consuming and requiring a reliable egg supply far in advance. Researchers are working on alternative production methods like using chicken eggs to produce antigens or developing a universal flu vaccine. The document provides various links to databases and information on using eggs in medical and pharmaceutical applications.
Hawaii - Vaccine Research - Advancing Humanity - Invest in Our Future
Hawaii - Vaccine Research - Advancing Humanity - Invest in Our FutureClifton M. Hasegawa & Associates, LLC
The document discusses the need for vaccines and exit strategies to end the COVID-19 crisis. It highlights research at the University of Hawaii that shows promise for a COVID-19 vaccine. The vaccine candidate developed by Dr. Axel Lehrer and his team successfully stimulated antibody and immune responses in mice, demonstrating potential to provide protection against SARS-CoV-2. If further research is successful, this could provide a path towards resolving the global pandemic.Mark Lipsitch: "Simulation and Deliberation to Prepare for Clinical Trials in...
Mark Lipsitch: "Simulation and Deliberation to Prepare for Clinical Trials in...The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics
Infectious disease emergencies are opportunities to test the efficacy of newly developed interventions (e.g. drugs, vaccines and treatment regimens), yet they raise many intertwined challenges of politics, logistics, ethics, and study design. Consistent with the efforts of CEPI, WHO, and others to encourage development and Phase I/II testing of candidate vaccines (the focus of this talk) in advance of emergencies, it is essential before the emergency strikes to advance the discussion of how such products can and should be tested. This can help to disentangle ethical from political and logistical concerns, reduce the time pressure to make a decision, and encourage rational deliberation by future stakeholders who at the time of deliberation do not know what role (which product, which field site) they may be supporting in an actual emergency.
At this luncheon, Professor Marc Lipsitch described his work on computer simulation of vaccine trials during epidemics to assess options for trial design, as well as some of his recent work on the ethics of trials in emergencies, with the aim to stimulate discussion on the intersection of these two topics.
For more, please see our website: http://petrieflom.law.harvard.edu/events/details/digital-health-harvard-series-november-2018Aaron Gilbertie and Dr. Jessica Seate - Welcome To The Aptimmune Symposium
Welcome To The Aptimmune Symposium - Aaron Gilbertie, CEO, Aptimmune; Dr. Jessica Seate, Professional Services Veterinarian, Aptimmune, from the 2018 Aptimmune Pre-AASV Symposium, March 2, 2018, San Diego, CA, USA.
More presentations at http://www.swinecast.com/2018-aptimmune-symposium-aasv
Session 4: Scaling up from one-to-one animal transmission experiments to epid...
This document discusses using modeling to link data across scales from individual animal transmission experiments to epidemiological models of national outbreaks. It describes how understanding transmission between individual animals informs biosecurity practices on farms and how understanding transmission between farms informs control policies. The document also discusses using hierarchical approximate Bayesian computation and Monte-Carlo Markov-Chain modeling to capture system variability and improve accuracy by incorporating individual herd and animal disease dynamics derived from experiments into regional between-farm models.
Tyson Foods - How Are We Applying What We've Learned
Tyson Foods applies a step-wise approach to food safety involving policy development, training, monitoring, auditing, and verification. This includes conducting applied research on intervention strategies in collaboration with academic researchers. Proprietary research at Tyson focuses on pathogens like Listeria monocytogenes, E. coli O157:H7, and Salmonella spp. through interventions like chemical formulations, thermal processing, and statistical validation. While foodborne illness trends have declined, Tyson is committed to the "Red Queen Principle" of continuous evolution to keep food safety standards high on farms and in production facilities.
Vaccine Conference| Osaka Conference| Immunology Conference
The document summarizes the tentative program for the 3rd International Conference on Vaccines & Vaccination to be held on May 26-27, 2020 in Osaka, Japan. The conference will focus on advances in immunology and vaccine technology, and will feature keynote speakers, oral presentations, workshops, and sessions on various topics like cancer vaccines, emerging diseases, diabetes vaccines, and more. It provides details on the conference schedule, highlights various presentation titles, and gives an overview of Osaka as the host city known for its universities, food, and modern architecture. Attendees are encouraged to register and submit abstracts for poster presentations and slots.
Marco safadi
- There was a significant reduction in cases of invasive bacterial infections like pneumococcal disease, H. influenzae, and meningococcal disease in 2020 coinciding with COVID-19 containment measures across many countries. Vaccination coverage rates have decreased dramatically in Brazil representing a potential risk of rebound in infectious disease rates. Maintaining disease surveillance is important to inform authorities on current disease burden and carriage rates even though some diseases were reduced during the pandemic.
Press Releases
This document contains press releases from three different studies:
1. A study finding that a bacterial molecule can train the immune system to tolerate infection without causing illness. This was reported by multiple news sources.
2. A study identifying anti-infective compounds from bacteria that could interrupt acute and persistent infections. This led to the founding of Spero Therapeutics.
3. A study identifying factors that can predict risk of multiple infections in patients with severe burns. This was also reported by multiple medical and science news organizations.
Ppt plegable 97
1. The document discusses two new diagnostic tests: one that can determine fetal sex from the mother's blood and one that can detect influenza infection using gold nanoparticles.
2. The fetal sex determination test analyzes DNA from the mother's blood to identify Y chromosome sequences and correctly identified sex with high accuracy after 7 weeks of gestation.
3. The influenza detection test uses gold nanoparticles linked to antibodies that aggregate around influenza viruses, allowing samples to be tested in minutes at low cost to help control the spread of infection.
Eto when all else fails 001
These documents discuss hospitals switching from high-level disinfection to ethylene oxide (EtO) gas sterilization of duodenoscopes in response to carbapenem-resistant Enterobacteriaceae (CRE) outbreaks. Investigations found the outbreaks were linked to contaminated duodenoscopes despite following reprocessing protocols. Hospitals that replaced high-level disinfection with EtO sterilization or implemented post-reprocessing testing did not have additional multidrug-resistant infections. The FDA and hospitals recommend EtO gas sterilization for reliably eliminating contamination from duodenoscopes.
Introduction to Computational Vaccinology and iVAX by EpiVax
This presentation was developed for Dr. Anna Durbin's vaccine class at Johns Hopkins. It was delivered simultaneously to my vaccine class at URI. Both classes had their first introductory lecture at the same time, so we joined them by webinar. The slides cover the EpiVax approach to computational vaccinology, which is relatively novel as compared to other groups working in the field. A number of case studies, including H7N9, are provided.
CEPI's 100 DAYS AMBITION - HOW DO WE DEVELOP A VACCINE IN 100 DAYS
CEPI's 100 Days Mission aims to develop a vaccine within 100 days from when a pathogen is sequenced or the need for a vaccine is recognized to initial availability. This would have allowed for vaccines to be available months earlier in the COVID-19 pandemic. CEPI is pursuing several strategies to achieve this goal, including developing prototype vaccine libraries for multiple virus families, building more distributed global manufacturing capacity, and rethinking clinical trial and regulatory approaches to allow for more real-world evidence collection in emergencies. The goal is extremely ambitious but CEPI believes that with vision and collaboration, significant improvements in response time are possible.
Platform Technologies to Accelerate Novel Vaccine Development and Manufacturing
Watch the presentation of this webinar here: https://bit.ly/3jmLYHu
State-of-the-art vaccine technologies are transforming vaccine development, and solutions for fast and reliable production are needed.
The vaccine industry has undergone a revolution in technology resulting in a variety of novel therapeutic platforms that accelerate development and significantly reduce the duration for process optimization and scale-up. However, challenges in maintaining efficacy and improving process robustness remain. In this presentation, we present a comparison of these novel technologies, discuss key considerations for manufacturing and share selected case studies for platforms such as virus-like-particles, viral vectors, plasmid DNA, and mRNA platform.
In this webinar, you will learn:
• Benefits of platform technologies in vaccine development
• Key considerations when deciding between platforms
• Vaccine pipeline analysis and selected case studies
Presented by:
David Loong, Ph.D, Senior Consultant, Novel Modalities Asia Pacific, Bioprocessing Strategy
Josephine Cheng, Senior Consultant, Core Modalities Asia Pacific, Bioprocessing Strategy
Platform Technologies to Accelerate Novel Vaccine Development and Manufacturing
Watch the presentation of this webinar here: https://bit.ly/3jmLYHu
State-of-the-art vaccine technologies are transforming vaccine development, and solutions for fast and reliable production are needed.
The vaccine industry has undergone a revolution in technology resulting in a variety of novel therapeutic platforms that accelerate development and significantly reduce the duration for process optimization and scale-up. However, challenges in maintaining efficacy and improving process robustness remain. In this presentation, we present a comparison of these novel technologies, discuss key considerations for manufacturing and share selected case studies for platforms such as virus-like-particles, viral vectors, plasmid DNA, and mRNA platform.
In this webinar, you will learn:
• Benefits of platform technologies in vaccine development
• Key considerations when deciding between platforms
• Vaccine pipeline analysis and selected case studies
Presented by:
David Loong, Ph.D, Senior Consultant, Novel Modalities Asia Pacific, Bioprocessing Strategy
Josephine Cheng, Senior Consultant, Core Modalities Asia Pacific, Bioprocessing Strategy
Chicken pox vaccine presentation jalandhar july 2017
Variped MSD data regarding 2 doses in India to be completed before the age of 2 years.
Jalandhar , July 2017 IAP
Dr Kirsty Le Doare @ MRF's Meningitis & Septicaemia
This document provides a summary of a presentation on prospects for developing a Group B Streptococcus (GBS) vaccine for pregnant women globally. It notes that GBS is a leading cause of neonatal infections and discusses the limitations of the current prevention strategy using intrapartum antibiotics. Developing a maternal GBS vaccine could have a higher impact by preventing more outcomes and providing more equitable coverage. Ongoing work includes further vaccine development and clinical trials, establishing a global disease burden, developing standardized assays to assess vaccine protection, and guidance for vaccine policy and implementation. The goal is to develop a safe and effective maternal GBS vaccine to reduce infant mortality from this disease worldwide.
HIV VACCINES; DEVELOPMENT AND CHALLENGES.pptx
This document discusses the development and challenges of HIV vaccines. Over 250 clinical trials have been conducted since the 1980s but an effective vaccine remains elusive due to biological challenges like HIV's ability to mutate. Newer vaccine approaches like mRNA vaccines show promise, with Moderna announcing positive results from a Phase 1 trial of their mRNA HIV vaccine. However, developing a vaccine that provides broad, long-lasting protection against diverse HIV strains and subtypes continues to be hampered by regulatory hurdles and a lack of funding that matches the burden of HIV in developing countries.
Current challenges in pertussis prevention gaurav gupta - sept 2016
Pentaxim, Hexaxim, India, pertussis, whooping cough, vaccine, 2 component, 5 component.
Talk for Chandigarh, India about whole cell pertussis versus acellular pertussis vaccine -
New Vaccines in the immediate pipeline - Slideset by Professor Susanna Esposito
Slideset by Professor Esposito on: Vaccines for adolescents/young adults/children; Maternal vaccines; Vaccines for the tropics.
It shows how several new vaccines will be available in the future with different targets and underlines the importance of better information and communication, that are keys to relevant use of vaccines.
Vaccine
This presentation summarizes the current prospects of vaccines in Bangladesh. It discusses the history of vaccine development, how vaccines work, examples of vaccines available in Bangladesh, and new vaccines under development. Recent developments in Bangladesh include introducing a new combination vaccine to prevent child pneumonia and meningitis. Future prospects include edible vaccines using transgenic plants, DNA vaccines, and recombinant protein vaccines offering improved safety, efficacy and cost effectiveness over current vaccines. Limitations of current vaccines include only preventing single diseases and having some adverse reactions and stability issues.
Dr Caroline Trotter @ MRF's Meningitis & Septicaemia in Children & Adults 2017
Dr Caroline Trotter @ MRF's Meningitis & Septicaemia in Children & Adults 2017Meningitis Research Foundation
A cost-effectiveness analysis was conducted on a potential group B Streptococcus (GBS) vaccine for the UK. The analysis found that a GBS vaccine is likely to be a cost-effective intervention based on recent UK data on disease burden and healthcare costs. A GBS vaccine covering 5 major serotypes could prevent hundreds of cases of neonatal and maternal GBS disease annually in the UK and gain thousands of quality-adjusted life years at a reasonable cost. Global analyses also indicate GBS vaccination could significantly reduce disease burden worldwide and be very cost-effective in many countries according to WHO guidelines. More research is still needed to define cost-effectiveness in lower-income settings.IAP Guidebook on immunization 2007
This document provides an overview of immunization in India. It discusses the historical development of immunization programs in India from the Expanded Program on Immunization (EPI) in 1978 to the current Universal Immunization Program (UIP). It also summarizes the basic concepts of immunology relevant to vaccination, including active vs passive immunization and factors that influence vaccine timing. The document outlines India's national immunization schedule and provides details on commonly used and newer vaccines. It addresses special considerations for immunization and discusses surveillance and monitoring of vaccine-preventable diseases in India.
Bacterialvaccine (1).ppt
Bacterial vaccines have helped eliminate or reduce several infectious diseases. Common bacterial vaccines protect against diphtheria, tetanus, pertussis, pneumococcal disease, Hib, meningococcal meningitis, typhoid, cholera and more. Vaccines work through active immunization by vaccination or passive immunization using antibodies. Ongoing research continues to develop new vaccines and improve vaccine effectiveness.
Katie Flanagan - Malaria vaccines current status and challenges
Vaccines are considered the most cost-effective means of control, prevention, elimination, eradication of infectious diseases: for this reason, a malaria vaccine would greatly assist in the drive to eradicate malaria from the world. Professor Flanagan presents in this slideset the current status and challenges of developing malaria vaccines.
To learn more, visit www.waidid.org!
Can Canadian Vaccine Research Survive the Challenges of Globalization?
1) Globalization of the vaccine industry has led major vaccine companies to conduct fewer clinical trials in Canada, threatening the stability of academic vaccine research centers.
2) A network of experienced vaccine trial centers in Canada could help attract more industry-sponsored studies and demonstrate value through world-class immunology research.
3) Program evaluation and research on vaccine effectiveness, safety, and value is increasingly important but underfunded in Canada; greater investment could distinguish Canada's research and improve immunization programs.
More Related Content
What's hot
Session 4: Scaling up from one-to-one animal transmission experiments to epid...
This document discusses using modeling to link data across scales from individual animal transmission experiments to epidemiological models of national outbreaks. It describes how understanding transmission between individual animals informs biosecurity practices on farms and how understanding transmission between farms informs control policies. The document also discusses using hierarchical approximate Bayesian computation and Monte-Carlo Markov-Chain modeling to capture system variability and improve accuracy by incorporating individual herd and animal disease dynamics derived from experiments into regional between-farm models.
Tyson Foods - How Are We Applying What We've Learned
Tyson Foods applies a step-wise approach to food safety involving policy development, training, monitoring, auditing, and verification. This includes conducting applied research on intervention strategies in collaboration with academic researchers. Proprietary research at Tyson focuses on pathogens like Listeria monocytogenes, E. coli O157:H7, and Salmonella spp. through interventions like chemical formulations, thermal processing, and statistical validation. While foodborne illness trends have declined, Tyson is committed to the "Red Queen Principle" of continuous evolution to keep food safety standards high on farms and in production facilities.
Vaccine Conference| Osaka Conference| Immunology Conference
The document summarizes the tentative program for the 3rd International Conference on Vaccines & Vaccination to be held on May 26-27, 2020 in Osaka, Japan. The conference will focus on advances in immunology and vaccine technology, and will feature keynote speakers, oral presentations, workshops, and sessions on various topics like cancer vaccines, emerging diseases, diabetes vaccines, and more. It provides details on the conference schedule, highlights various presentation titles, and gives an overview of Osaka as the host city known for its universities, food, and modern architecture. Attendees are encouraged to register and submit abstracts for poster presentations and slots.
Marco safadi
- There was a significant reduction in cases of invasive bacterial infections like pneumococcal disease, H. influenzae, and meningococcal disease in 2020 coinciding with COVID-19 containment measures across many countries. Vaccination coverage rates have decreased dramatically in Brazil representing a potential risk of rebound in infectious disease rates. Maintaining disease surveillance is important to inform authorities on current disease burden and carriage rates even though some diseases were reduced during the pandemic.
Press Releases
This document contains press releases from three different studies:
1. A study finding that a bacterial molecule can train the immune system to tolerate infection without causing illness. This was reported by multiple news sources.
2. A study identifying anti-infective compounds from bacteria that could interrupt acute and persistent infections. This led to the founding of Spero Therapeutics.
3. A study identifying factors that can predict risk of multiple infections in patients with severe burns. This was also reported by multiple medical and science news organizations.
Ppt plegable 97
1. The document discusses two new diagnostic tests: one that can determine fetal sex from the mother's blood and one that can detect influenza infection using gold nanoparticles.
2. The fetal sex determination test analyzes DNA from the mother's blood to identify Y chromosome sequences and correctly identified sex with high accuracy after 7 weeks of gestation.
3. The influenza detection test uses gold nanoparticles linked to antibodies that aggregate around influenza viruses, allowing samples to be tested in minutes at low cost to help control the spread of infection.
Eto when all else fails 001
These documents discuss hospitals switching from high-level disinfection to ethylene oxide (EtO) gas sterilization of duodenoscopes in response to carbapenem-resistant Enterobacteriaceae (CRE) outbreaks. Investigations found the outbreaks were linked to contaminated duodenoscopes despite following reprocessing protocols. Hospitals that replaced high-level disinfection with EtO sterilization or implemented post-reprocessing testing did not have additional multidrug-resistant infections. The FDA and hospitals recommend EtO gas sterilization for reliably eliminating contamination from duodenoscopes.
What's hot (7)
Session 4: Scaling up from one-to-one animal transmission experiments to epid...
Session 4: Scaling up from one-to-one animal transmission experiments to epid...
Tyson Foods - How Are We Applying What We've Learned
Tyson Foods - How Are We Applying What We've Learned
Vaccine Conference| Osaka Conference| Immunology Conference
Vaccine Conference| Osaka Conference| Immunology Conference
Similar to Developing Better Methods of Cross-Reactive Influenza Vaccine Production
Introduction to Computational Vaccinology and iVAX by EpiVax
This presentation was developed for Dr. Anna Durbin's vaccine class at Johns Hopkins. It was delivered simultaneously to my vaccine class at URI. Both classes had their first introductory lecture at the same time, so we joined them by webinar. The slides cover the EpiVax approach to computational vaccinology, which is relatively novel as compared to other groups working in the field. A number of case studies, including H7N9, are provided.
CEPI's 100 DAYS AMBITION - HOW DO WE DEVELOP A VACCINE IN 100 DAYS
CEPI's 100 Days Mission aims to develop a vaccine within 100 days from when a pathogen is sequenced or the need for a vaccine is recognized to initial availability. This would have allowed for vaccines to be available months earlier in the COVID-19 pandemic. CEPI is pursuing several strategies to achieve this goal, including developing prototype vaccine libraries for multiple virus families, building more distributed global manufacturing capacity, and rethinking clinical trial and regulatory approaches to allow for more real-world evidence collection in emergencies. The goal is extremely ambitious but CEPI believes that with vision and collaboration, significant improvements in response time are possible.
Platform Technologies to Accelerate Novel Vaccine Development and Manufacturing
Watch the presentation of this webinar here: https://bit.ly/3jmLYHu
State-of-the-art vaccine technologies are transforming vaccine development, and solutions for fast and reliable production are needed.
The vaccine industry has undergone a revolution in technology resulting in a variety of novel therapeutic platforms that accelerate development and significantly reduce the duration for process optimization and scale-up. However, challenges in maintaining efficacy and improving process robustness remain. In this presentation, we present a comparison of these novel technologies, discuss key considerations for manufacturing and share selected case studies for platforms such as virus-like-particles, viral vectors, plasmid DNA, and mRNA platform.
In this webinar, you will learn:
• Benefits of platform technologies in vaccine development
• Key considerations when deciding between platforms
• Vaccine pipeline analysis and selected case studies
Presented by:
David Loong, Ph.D, Senior Consultant, Novel Modalities Asia Pacific, Bioprocessing Strategy
Josephine Cheng, Senior Consultant, Core Modalities Asia Pacific, Bioprocessing Strategy
Platform Technologies to Accelerate Novel Vaccine Development and Manufacturing
Watch the presentation of this webinar here: https://bit.ly/3jmLYHu
State-of-the-art vaccine technologies are transforming vaccine development, and solutions for fast and reliable production are needed.
The vaccine industry has undergone a revolution in technology resulting in a variety of novel therapeutic platforms that accelerate development and significantly reduce the duration for process optimization and scale-up. However, challenges in maintaining efficacy and improving process robustness remain. In this presentation, we present a comparison of these novel technologies, discuss key considerations for manufacturing and share selected case studies for platforms such as virus-like-particles, viral vectors, plasmid DNA, and mRNA platform.
In this webinar, you will learn:
• Benefits of platform technologies in vaccine development
• Key considerations when deciding between platforms
• Vaccine pipeline analysis and selected case studies
Presented by:
David Loong, Ph.D, Senior Consultant, Novel Modalities Asia Pacific, Bioprocessing Strategy
Josephine Cheng, Senior Consultant, Core Modalities Asia Pacific, Bioprocessing Strategy
Chicken pox vaccine presentation jalandhar july 2017
Variped MSD data regarding 2 doses in India to be completed before the age of 2 years.
Jalandhar , July 2017 IAP
Dr Kirsty Le Doare @ MRF's Meningitis & Septicaemia
This document provides a summary of a presentation on prospects for developing a Group B Streptococcus (GBS) vaccine for pregnant women globally. It notes that GBS is a leading cause of neonatal infections and discusses the limitations of the current prevention strategy using intrapartum antibiotics. Developing a maternal GBS vaccine could have a higher impact by preventing more outcomes and providing more equitable coverage. Ongoing work includes further vaccine development and clinical trials, establishing a global disease burden, developing standardized assays to assess vaccine protection, and guidance for vaccine policy and implementation. The goal is to develop a safe and effective maternal GBS vaccine to reduce infant mortality from this disease worldwide.
HIV VACCINES; DEVELOPMENT AND CHALLENGES.pptx
This document discusses the development and challenges of HIV vaccines. Over 250 clinical trials have been conducted since the 1980s but an effective vaccine remains elusive due to biological challenges like HIV's ability to mutate. Newer vaccine approaches like mRNA vaccines show promise, with Moderna announcing positive results from a Phase 1 trial of their mRNA HIV vaccine. However, developing a vaccine that provides broad, long-lasting protection against diverse HIV strains and subtypes continues to be hampered by regulatory hurdles and a lack of funding that matches the burden of HIV in developing countries.
Current challenges in pertussis prevention gaurav gupta - sept 2016
Pentaxim, Hexaxim, India, pertussis, whooping cough, vaccine, 2 component, 5 component.
Talk for Chandigarh, India about whole cell pertussis versus acellular pertussis vaccine -
New Vaccines in the immediate pipeline - Slideset by Professor Susanna Esposito
Slideset by Professor Esposito on: Vaccines for adolescents/young adults/children; Maternal vaccines; Vaccines for the tropics.
It shows how several new vaccines will be available in the future with different targets and underlines the importance of better information and communication, that are keys to relevant use of vaccines.
Vaccine
This presentation summarizes the current prospects of vaccines in Bangladesh. It discusses the history of vaccine development, how vaccines work, examples of vaccines available in Bangladesh, and new vaccines under development. Recent developments in Bangladesh include introducing a new combination vaccine to prevent child pneumonia and meningitis. Future prospects include edible vaccines using transgenic plants, DNA vaccines, and recombinant protein vaccines offering improved safety, efficacy and cost effectiveness over current vaccines. Limitations of current vaccines include only preventing single diseases and having some adverse reactions and stability issues.
Dr Caroline Trotter @ MRF's Meningitis & Septicaemia in Children & Adults 2017
Dr Caroline Trotter @ MRF's Meningitis & Septicaemia in Children & Adults 2017Meningitis Research Foundation
A cost-effectiveness analysis was conducted on a potential group B Streptococcus (GBS) vaccine for the UK. The analysis found that a GBS vaccine is likely to be a cost-effective intervention based on recent UK data on disease burden and healthcare costs. A GBS vaccine covering 5 major serotypes could prevent hundreds of cases of neonatal and maternal GBS disease annually in the UK and gain thousands of quality-adjusted life years at a reasonable cost. Global analyses also indicate GBS vaccination could significantly reduce disease burden worldwide and be very cost-effective in many countries according to WHO guidelines. More research is still needed to define cost-effectiveness in lower-income settings.IAP Guidebook on immunization 2007
This document provides an overview of immunization in India. It discusses the historical development of immunization programs in India from the Expanded Program on Immunization (EPI) in 1978 to the current Universal Immunization Program (UIP). It also summarizes the basic concepts of immunology relevant to vaccination, including active vs passive immunization and factors that influence vaccine timing. The document outlines India's national immunization schedule and provides details on commonly used and newer vaccines. It addresses special considerations for immunization and discusses surveillance and monitoring of vaccine-preventable diseases in India.
Bacterialvaccine (1).ppt
Bacterial vaccines have helped eliminate or reduce several infectious diseases. Common bacterial vaccines protect against diphtheria, tetanus, pertussis, pneumococcal disease, Hib, meningococcal meningitis, typhoid, cholera and more. Vaccines work through active immunization by vaccination or passive immunization using antibodies. Ongoing research continues to develop new vaccines and improve vaccine effectiveness.
Katie Flanagan - Malaria vaccines current status and challenges
Vaccines are considered the most cost-effective means of control, prevention, elimination, eradication of infectious diseases: for this reason, a malaria vaccine would greatly assist in the drive to eradicate malaria from the world. Professor Flanagan presents in this slideset the current status and challenges of developing malaria vaccines.
To learn more, visit www.waidid.org!
Can Canadian Vaccine Research Survive the Challenges of Globalization?
1) Globalization of the vaccine industry has led major vaccine companies to conduct fewer clinical trials in Canada, threatening the stability of academic vaccine research centers.
2) A network of experienced vaccine trial centers in Canada could help attract more industry-sponsored studies and demonstrate value through world-class immunology research.
3) Program evaluation and research on vaccine effectiveness, safety, and value is increasingly important but underfunded in Canada; greater investment could distinguish Canada's research and improve immunization programs.
Medicago Investor Presentation - October 20, 2009
This investor presentation by Medicago discusses their plant-based influenza vaccine technology as a rapid response solution for pandemic influenza. Medicago believes their platform can produce vaccines in a fraction of the time required by traditional egg-based methods, allowing vaccines to be available before a pandemic wave begins. Clinical results so far show the H5N1 VLP vaccine produced by Medicago induces a strong immune response and cross-protection against different strains after a single low dose. Medicago aims to advance their pandemic flu vaccine through Phase I/II clinical trials with the goal of potential commercialization in 2013.
Malaria vaccine
This document provides information about malaria vaccines. It discusses the context of malaria globally and the need for a vaccine. Several potential vaccine candidates target different stages of the malaria parasite's lifecycle, including sporozoites, infected hepatocytes, and erythrocytic stages. Developing an effective vaccine is challenging due to the parasite's diversity and complexity. The most promising current candidate is RTS,S, which provides some protection against malaria in clinical trials but is not fully effective.
Dr. A. Sumathi - Mucosal Delivery of Vaccines
The document discusses various strategies for mucosal delivery of vaccines. It describes how different delivery systems are designed to increase antigen delivery across mucosal surfaces, protect antigens from degradation, and facilitate clearance in the local mucosal environment. Live bacteria and viruses as well as polymeric particles such as synthetic polymers like PLGA and natural polymers like chitosan have been used. Inorganic particles including silica and gold nanoparticles have also been explored as vaccine delivery vehicles to the mucosa.
Webinar: Defeating Superbugs: Hospitals on the Front Lines
About the Webinar: Defeating Superbugs: Hospitals on the Front Lines
http://www.modernhealthcare.com/article/20140917/INFO/309179926
Hospitals across the country are facing a grim reality in which some of the most deadly healthcare-associated infections they encounter are untreatable with first- or even second-line antibiotics. These “superbugs” affect at least 2 million Americans each year and lead to 23,000 deaths. And their threat is growing, public health officials warn. This editorial webinar and “Defeating Superbugs” white paper will explore the steps providers must take to ramp up surveillance efforts, promote appropriate antibiotic use and control outbreaks. Our panel of experts will share their organizations' experiences as well as proven strategies for success.
Registration for this webinar includes Modern Healthcare's “Defeating Superbugs” white paper, with proven tips and strategies for promoting appropriate antibiotic use, improving infection surveillance, identifying drug-resistant infections and dealing with outbreaks.
KEY TAKEAWAYS
- Best practices for effective antimicrobial stewardship
- Real-world examples of effective interventions, including universal rapid testing for drug-resistant MRSA
- Tips for engaging senior leadership
- Aggressive strategies for controlling outbreaks
PANELISTS
Lance Peterson
Director of the Clinical Microbiology and Infectious Disease Research Division
NorthShore University HealthSystem, Evanston, Ill.
Anurag Malani
Medical Director for the Infection Prevention and Antimicrobial Stewardship Programs
St. Joseph Mercy Hospital, Ann Arbor, Mich.
Robert Weinstein
Chief Medical Officer for Population Health
Chairman of the Department of Medicine, Cook County Health and Hospitals System; Professor, Rush University Medical Center, Chicago
MODERATOR
Maureen McKinney
Editorial Programs Manager
Modern Healthcare
Global hiv vaccine market future outlook
"Global HIV Vaccine Market Future Outlook" Report Highlights:
Introduction to HIV Vaccines
Issues Related to the Development of HIV Vaccines
Parameters for Successful Commercialization of HIV Vaccines
Global HIV Vaccines Market Opportunity Analysis
Global HIV Vaccine Clinical Pipeline by Company & Phase
Global HIV Vaccine Clinical Pipeline: 100 Vaccines
Majority Vaccine in Preclinical Phase: 42 Vaccines
Similar to Developing Better Methods of Cross-Reactive Influenza Vaccine Production (20)
Introduction to Computational Vaccinology and iVAX by EpiVax
Introduction to Computational Vaccinology and iVAX by EpiVax
CEPI's 100 DAYS AMBITION - HOW DO WE DEVELOP A VACCINE IN 100 DAYS
CEPI's 100 DAYS AMBITION - HOW DO WE DEVELOP A VACCINE IN 100 DAYS
Platform Technologies to Accelerate Novel Vaccine Development and Manufacturing
Platform Technologies to Accelerate Novel Vaccine Development and Manufacturing
Platform Technologies to Accelerate Novel Vaccine Development and Manufacturing
Platform Technologies to Accelerate Novel Vaccine Development and Manufacturing
Chicken pox vaccine presentation jalandhar july 2017
Chicken pox vaccine presentation jalandhar july 2017
Dr Kirsty Le Doare @ MRF's Meningitis & Septicaemia
Dr Kirsty Le Doare @ MRF's Meningitis & Septicaemia
Current challenges in pertussis prevention gaurav gupta - sept 2016
Current challenges in pertussis prevention gaurav gupta - sept 2016
New Vaccines in the immediate pipeline - Slideset by Professor Susanna Esposito
New Vaccines in the immediate pipeline - Slideset by Professor Susanna Esposito
Dr Caroline Trotter @ MRF's Meningitis & Septicaemia in Children & Adults 2017
Dr Caroline Trotter @ MRF's Meningitis & Septicaemia in Children & Adults 2017
Katie Flanagan - Malaria vaccines current status and challenges
Katie Flanagan - Malaria vaccines current status and challenges
Can Canadian Vaccine Research Survive the Challenges of Globalization?
Can Canadian Vaccine Research Survive the Challenges of Globalization?
Webinar: Defeating Superbugs: Hospitals on the Front Lines
Webinar: Defeating Superbugs: Hospitals on the Front Lines
Recently uploaded
Mechanical Engineering on AAI Summer Training Report-003.pdf
Mechanical Engineering PROJECT REPORT ON SUMMER VOCATIONAL TRAINING
AT MBB AIRPORT
学校原版美国波士顿大学毕业证学历学位证书原版一模一样
原版一模一样【微信：741003700 】【美国波士顿大学毕业证学历学位证书】【微信：741003700 】学位证，留信认证（真实可查，永久存档）offer、雅思、外壳等材料/诚信可靠,可直接看成品样本，帮您解决无法毕业带来的各种难题！外壳，原版制作，诚信可靠，可直接看成品样本。行业标杆！精益求精，诚心合作，真诚制作！多年品质 ,按需精细制作，24小时接单,全套进口原装设备。十五年致力于帮助留学生解决难题，包您满意。
本公司拥有海外各大学样板无数，能完美还原海外各大学 Bachelor Diploma degree, Master Degree Diploma
1:1完美还原海外各大学毕业材料上的工艺：水印，阴影底纹，钢印LOGO烫金烫银，LOGO烫金烫银复合重叠。文字图案浮雕、激光镭射、紫外荧光、温感、复印防伪等防伪工艺。材料咨询办理、认证咨询办理请加学历顾问Q/微741003700
留信网认证的作用:
1:该专业认证可证明留学生真实身份
2:同时对留学生所学专业登记给予评定
3:国家专业人才认证中心颁发入库证书
4:这个认证书并且可以归档倒地方
5:凡事获得留信网入网的信息将会逐步更新到个人身份内，将在公安局网内查询个人身份证信息后，同步读取人才网入库信息
6:个人职称评审加20分
7:个人信誉贷款加10分
8:在国家人才网主办的国家网络招聘大会中纳入资料，供国家高端企业选择人才
原版制作(Humboldt毕业证书)柏林大学毕业证学位证一模一样
原件一模一样【微信：bwp0011】《(Humboldt毕业证书)柏林大学毕业证学位证》【微信：bwp0011】学位证，留信认证（真实可查，永久存档）原件一模一样纸张工艺/offer、雅思、外壳等材料/诚信可靠,可直接看成品样本，帮您解决无法毕业带来的各种难题！外壳，原版制作，诚信可靠，可直接看成品样本。行业标杆！精益求精，诚心合作，真诚制作！多年品质 ,按需精细制作，24小时接单,全套进口原装设备。十五年致力于帮助留学生解决难题，包您满意。
本公司拥有海外各大学样板无数，能完美还原。
1:1完美还原海外各大学毕业材料上的工艺：水印，阴影底纹，钢印LOGO烫金烫银，LOGO烫金烫银复合重叠。文字图案浮雕、激光镭射、紫外荧光、温感、复印防伪等防伪工艺。材料咨询办理、认证咨询办理请加学历顾问微bwp0011
【主营项目】
一.毕业证【微bwp0011】成绩单、使馆认证、教育部认证、雅思托福成绩单、学生卡等！
二.真实使馆公证(即留学回国人员证明,不成功不收费)
三.真实教育部学历学位认证（教育部存档！教育部留服网站永久可查）
四.办理各国各大学文凭(一对一专业服务,可全程监控跟踪进度)
如果您处于以下几种情况：
◇在校期间，因各种原因未能顺利毕业……拿不到官方毕业证【微bwp0011】
◇面对父母的压力，希望尽快拿到；
◇不清楚认证流程以及材料该如何准备；
◇回国时间很长，忘记办理；
◇回国马上就要找工作，办给用人单位看；
◇企事业单位必须要求办理的
◇需要报考公务员、购买免税车、落转户口
◇申请留学生创业基金
留信网认证的作用:
1:该专业认证可证明留学生真实身份
2:同时对留学生所学专业登记给予评定
3:国家专业人才认证中心颁发入库证书
4:这个认证书并且可以归档倒地方
5:凡事获得留信网入网的信息将会逐步更新到个人身份内，将在公安局网内查询个人身份证信息后，同步读取人才网入库信息
6:个人职称评审加20分
7:个人信誉贷款加10分
8:在国家人才网主办的国家网络招聘大会中纳入资料，供国家高端企业选择人才
Rainfall intensity duration frequency curve statistical analysis and modeling...
Using data from 41 years in Patna’ India’ the study’s goal is to analyze the trends of how often it rains on a weekly, seasonal, and annual basis (1981−2020). First, utilizing the intensity-duration-frequency (IDF) curve and the relationship by statistically analyzing rainfall’ the historical rainfall data set for Patna’ India’ during a 41 year period (1981−2020), was evaluated for its quality. Changes in the hydrologic cycle as a result of increased greenhouse gas emissions are expected to induce variations in the intensity, length, and frequency of precipitation events. One strategy to lessen vulnerability is to quantify probable changes and adapt to them. Techniques such as log-normal, normal, and Gumbel are used (EV-I). Distributions were created with durations of 1, 2, 3, 6, and 24 h and return times of 2, 5, 10, 25, and 100 years. There were also mathematical correlations discovered between rainfall and recurrence interval.
Findings: Based on findings, the Gumbel approach produced the highest intensity values, whereas the other approaches produced values that were close to each other. The data indicates that 461.9 mm of rain fell during the monsoon season’s 301st week. However, it was found that the 29th week had the greatest average rainfall, 92.6 mm. With 952.6 mm on average, the monsoon season saw the highest rainfall. Calculations revealed that the yearly rainfall averaged 1171.1 mm. Using Weibull’s method, the study was subsequently expanded to examine rainfall distribution at different recurrence intervals of 2, 5, 10, and 25 years. Rainfall and recurrence interval mathematical correlations were also developed. Further regression analysis revealed that short wave irrigation, wind direction, wind speed, pressure, relative humidity, and temperature all had a substantial influence on rainfall.
Originality and value: The results of the rainfall IDF curves can provide useful information to policymakers in making appropriate decisions in managing and minimizing floods in the study area.
Advanced control scheme of doubly fed induction generator for wind turbine us...
This paper describes a speed control device for generating electrical energy on an electricity network based on the doubly fed induction generator (DFIG) used for wind power conversion systems. At first, a double-fed induction generator model was constructed. A control law is formulated to govern the flow of energy between the stator of a DFIG and the energy network using three types of controllers: proportional integral (PI), sliding mode controller (SMC) and second order sliding mode controller (SOSMC). Their different results in terms of power reference tracking, reaction to unexpected speed fluctuations, sensitivity to perturbations, and resilience against machine parameter alterations are compared. MATLAB/Simulink was used to conduct the simulations for the preceding study. Multiple simulations have shown very satisfying results, and the investigations demonstrate the efficacy and power-enhancing capabilities of the suggested control system.
哪里办理(csu毕业证书)查尔斯特大学毕业证硕士学历原版一模一样
原版一模一样【微信：741003700 】【(csu毕业证书)查尔斯特大学毕业证硕士学历】【微信：741003700 】学位证，留信认证（真实可查，永久存档）offer、雅思、外壳等材料/诚信可靠,可直接看成品样本，帮您解决无法毕业带来的各种难题！外壳，原版制作，诚信可靠，可直接看成品样本。行业标杆！精益求精，诚心合作，真诚制作！多年品质 ,按需精细制作，24小时接单,全套进口原装设备。十五年致力于帮助留学生解决难题，包您满意。
本公司拥有海外各大学样板无数，能完美还原海外各大学 Bachelor Diploma degree, Master Degree Diploma
1:1完美还原海外各大学毕业材料上的工艺：水印，阴影底纹，钢印LOGO烫金烫银，LOGO烫金烫银复合重叠。文字图案浮雕、激光镭射、紫外荧光、温感、复印防伪等防伪工艺。材料咨询办理、认证咨询办理请加学历顾问Q/微741003700
留信网认证的作用:
1:该专业认证可证明留学生真实身份
2:同时对留学生所学专业登记给予评定
3:国家专业人才认证中心颁发入库证书
4:这个认证书并且可以归档倒地方
5:凡事获得留信网入网的信息将会逐步更新到个人身份内，将在公安局网内查询个人身份证信息后，同步读取人才网入库信息
6:个人职称评审加20分
7:个人信誉贷款加10分
8:在国家人才网主办的国家网络招聘大会中纳入资料，供国家高端企业选择人才
Null Bangalore | Pentesters Approach to AWS IAM
#Abstract:
- Learn more about the real-world methods for auditing AWS IAM (Identity and Access Management) as a pentester. So let us proceed with a brief discussion of IAM as well as some typical misconfigurations and their potential exploits in order to reinforce the understanding of IAM security best practices.
- Gain actionable insights into AWS IAM policies and roles, using hands on approach.
#Prerequisites:
- Basic understanding of AWS services and architecture
- Familiarity with cloud security concepts
- Experience using the AWS Management Console or AWS CLI.
- For hands on lab create account on [killercoda.com](https://killercoda.com/cloudsecurity-scenario/)
# Scenario Covered:
- Basics of IAM in AWS
- Implementing IAM Policies with Least Privilege to Manage S3 Bucket
- Objective: Create an S3 bucket with least privilege IAM policy and validate access.
- Steps:
- Create S3 bucket.
- Attach least privilege policy to IAM user.
- Validate access.
- Exploiting IAM PassRole Misconfiguration
-Allows a user to pass a specific IAM role to an AWS service (ec2), typically used for service access delegation. Then exploit PassRole Misconfiguration granting unauthorized access to sensitive resources.
- Objective: Demonstrate how a PassRole misconfiguration can grant unauthorized access.
- Steps:
- Allow user to pass IAM role to EC2.
- Exploit misconfiguration for unauthorized access.
- Access sensitive resources.
- Exploiting IAM AssumeRole Misconfiguration with Overly Permissive Role
- An overly permissive IAM role configuration can lead to privilege escalation by creating a role with administrative privileges and allow a user to assume this role.
- Objective: Show how overly permissive IAM roles can lead to privilege escalation.
- Steps:
- Create role with administrative privileges.
- Allow user to assume the role.
- Perform administrative actions.
- Differentiation between PassRole vs AssumeRole
Try at [killercoda.com](https://killercoda.com/cloudsecurity-scenario/)
Embedded machine learning-based road conditions and driving behavior monitoring
Car accident rates have increased in recent years, resulting in losses in human lives, properties, and other financial costs. An embedded machine learning-based system is developed to address this critical issue. The system can monitor road conditions, detect driving patterns, and identify aggressive driving behaviors. The system is based on neural networks trained on a comprehensive dataset of driving events, driving styles, and road conditions. The system effectively detects potential risks and helps mitigate the frequency and impact of accidents. The primary goal is to ensure the safety of drivers and vehicles. Collecting data involved gathering information on three key road events: normal street and normal drive, speed bumps, circular yellow speed bumps, and three aggressive driving actions: sudden start, sudden stop, and sudden entry. The gathered data is processed and analyzed using a machine learning system designed for limited power and memory devices. The developed system resulted in 91.9% accuracy, 93.6% precision, and 92% recall. The achieved inference time on an Arduino Nano 33 BLE Sense with a 32-bit CPU running at 64 MHz is 34 ms and requires 2.6 kB peak RAM and 139.9 kB program flash memory, making it suitable for resource-constrained embedded systems.
Redefining brain tumor segmentation: a cutting-edge convolutional neural netw...
Medical image analysis has witnessed significant advancements with deep learning techniques. In the domain of brain tumor segmentation, the ability to
precisely delineate tumor boundaries from magnetic resonance imaging (MRI)
scans holds profound implications for diagnosis. This study presents an ensemble convolutional neural network (CNN) with transfer learning, integrating
the state-of-the-art Deeplabv3+ architecture with the ResNet18 backbone. The
model is rigorously trained and evaluated, exhibiting remarkable performance
metrics, including an impressive global accuracy of 99.286%, a high-class accuracy of 82.191%, a mean intersection over union (IoU) of 79.900%, a weighted
IoU of 98.620%, and a Boundary F1 (BF) score of 83.303%. Notably, a detailed comparative analysis with existing methods showcases the superiority of
our proposed model. These findings underscore the model’s competence in precise brain tumor localization, underscoring its potential to revolutionize medical
image analysis and enhance healthcare outcomes. This research paves the way
for future exploration and optimization of advanced CNN models in medical
imaging, emphasizing addressing false positives and resource efficiency.
Software Engineering and Project Management - Introduction, Modeling Concepts...
Introduction, Modeling Concepts and Class Modeling: What is Object orientation? What is OO development? OO Themes; Evidence for usefulness of OO development; OO modeling history. Modeling
as Design technique: Modeling, abstraction, The Three models. Class Modeling: Object and Class Concept, Link and associations concepts, Generalization and Inheritance, A sample class model, Navigation of class models, and UML diagrams
Building the Analysis Models: Requirement Analysis, Analysis Model Approaches, Data modeling Concepts, Object Oriented Analysis, Scenario-Based Modeling, Flow-Oriented Modeling, class Based Modeling, Creating a Behavioral Model.
Data Driven Maintenance | UReason Webinar
Discover the latest insights on Data Driven Maintenance with our comprehensive webinar presentation. Learn about traditional maintenance challenges, the right approach to utilizing data, and the benefits of adopting a Data Driven Maintenance strategy. Explore real-world examples, industry best practices, and innovative solutions like FMECA and the D3M model. This presentation, led by expert Jules Oudmans, is essential for asset owners looking to optimize their maintenance processes and leverage digital technologies for improved efficiency and performance. Download now to stay ahead in the evolving maintenance landscape.
Recently uploaded (20)
Mechanical Engineering on AAI Summer Training Report-003.pdf
Mechanical Engineering on AAI Summer Training Report-003.pdf
Manufacturing Process of molasses based distillery ppt.pptx
Manufacturing Process of molasses based distillery ppt.pptx
Rainfall intensity duration frequency curve statistical analysis and modeling...
Rainfall intensity duration frequency curve statistical analysis and modeling...
Advanced control scheme of doubly fed induction generator for wind turbine us...
Advanced control scheme of doubly fed induction generator for wind turbine us...
Embedded machine learning-based road conditions and driving behavior monitoring
Embedded machine learning-based road conditions and driving behavior monitoring
Redefining brain tumor segmentation: a cutting-edge convolutional neural netw...
Redefining brain tumor segmentation: a cutting-edge convolutional neural netw...
Software Engineering and Project Management - Introduction, Modeling Concepts...
Software Engineering and Project Management - Introduction, Modeling Concepts...
Engineering Drawings Lecture Detail Drawings 2014.pdf
Engineering Drawings Lecture Detail Drawings 2014.pdf
Data Control Language.pptx Data Control Language.pptx
Data Control Language.pptx Data Control Language.pptx
Developing Better Methods of Cross-Reactive Influenza Vaccine Production
- 1. Methodology Introduction Hypothesis Objectives Expected Results . References Conclusions Photo or graphic caption Towards Developing Better Methods of Cross-Reactive Influenza Vaccine Production Michael Bodanza (CM) & Ryan Bowe (CM) Advisor: Professor Susan C. Roberts (CM) Vaccines combatting the influenza virus struggle to keep pace with the virus’ rapid mutation rate, leading to widely ineffective vaccines. This problem is compounded by the lengthy timescale of current development methods Selection of Strain Testing Production and shipping Large Scale Vaccination Jan ̶ ̶ ̶ ̶ ̶ ̶ ̶ ̶ ̶ ̶ ̶ ̶ ̶ ̶ ̶ ̶ ̶ ̶ ̶ ̶ ̶ ̶ May Jun ̶ ̶ ̶ ̶ ̶ Jul Aug ̶ ̶ ̶ ̶ ̶ ̶ ̶ ̶ ̶ Sep Oct ̶ ̶ ̶ ̶ ̶ ̶ ̶ ̶ ̶ ̶ ̶ ̶ ̶ ̶ ̶ ̶ ̶ ̶ ̶ ̶ ̶ ̶ ̶ Dec Using chimeric Virus Like Particles (VLPs) the production rate and reliability of influenza vaccines could improve dramatically with the insertion of the conserved 55 amino acid- long alpha helix (LAH) HA M1 HA/M1 VLPs • Has a reduced production time frame • Has high efficacy percentages • Has the ability to be used across multiple strains of influenza 1. To Create a Vaccine that: 2. To create a genetically modified tobacco plant that can produce influenza VLPs Create a GM Tobacco using HA/M1 gene likely utilizing Agrobacterium tumefaciens as a vector Produce VLPs corresponding to the target influenza strain Insert LAH protein with tandem core technology Inject vaccine into mice and ferrets and expose to influenzas A, B, and C to test for effectiveness and broadness Other experiments utilizing similar technology and methods saw promising results: • H1N1 VLP Production saw over 10 million doses of the vaccine made in 1 month • A specific H7 vaccine saw 100% effectiveness against H7N9 influenza A • Utilization of LAH has shown strong cross-protections against multiple influenza strains Ideally, this new method could help prevent the severity of pandemics by allowing for broad, effective, and quickly produced vaccines. This can also give insight into further use of plants as sources of vaccines combatting viruses “Influenza (Flu).” Centers for Disease Control and Prevention, Centers for Disease Control and Prevention, 5 Oct. 2017, www.cdc.gov/flu/about/index.html. Pillet, S., et al. “Plant-Derived H7 VLP vaccine elicits protective immune response against H7N9 influenza virus in mice and ferrets.” Vaccine, vol. 33, no. 46, 2015, pp. 6282–6289., doi:10.1016/j.vaccine.2015.09.065. Globalbiodefense. Avaialble from: https://globalbiodefense.com/2012/07/28/darpa-program-hits- milestone-in-plant-based-vaccines-for-pandemics/ Kazaks, A., et al. "Production and purification of chimeric HBc virus-like particles carrying influenza virus LAH domain as vaccine candidates." BMC Biotechnology, vol. 17, no. 1, 2017. Science in Context, Dybdal, S. “Plant based vaccines are medicine of the future.” Sciencenordic.com, “Seasonal Flu Vaccine Effectiveness.” Center for Disease Control and Prevention, CDC, 15 Feb. 2018, www.cdc.gov/flu/images/professionals/vaccination/seasonal-flu-vaccine-effeciveness.jpg. Lowy, Douglas R. “Assembly of L1 VLP vs. Assembly of Authentic Virus.” The Journal of Clinical Investigation, JCI, 4 Jan. 2016, dm5migu4zj3pb.cloudfront.net/manuscripts/85000/85446/medium/JCI85446.f1.jpg. Bedford, Trevor. “Phylogenetic Trees of Different Influenza Lineages.” Bedford Labs, Harvard School of Public Health, 3 Mar. 2016, bedford.io/images/talks/flu_trees.png. Yang, Ming, et al. “Expression of HBcAg-ZDIII in N. Benthamiana Plants.” Scientific Reports, Nature, 17 May 2017, media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-017-08247- 9/MediaObjects/41598_2017_8247_Fig1_HTML.jpg. Naik, Gautam. “Making Vaccines from Plants.” Wall Street Journal, 24 Feb. 2010, si.wsj.net/public/resources/images/NA- BE526C_PLANT_NS_20100223211027.gif. Pniewski, Tomasz. “Potential Plant-Derived Parenteral and Oral Vaccines for Immunization.”International Journal of Molecular Sciences, Institute of Plant Genetics, 17 Dec. 2012, www.mdpi.com/ijms/ijms-14-01978/article_deploy/html/images/ijms-14-01978-s001.png. Yellow: surface antigen Blue: Core protein Red: viral DNA